Annals of Hematology

, Volume 63, Issue 1, pp 15–19 | Cite as

Treatment of early stage-B chronic lymphocytic leukemia with alpha-2b interferon after chlorambucil reduction of the tumoral mass

  • E. Montserrat
  • N. Villamor
  • A. Urbano-Ispizua
  • J. M. Ribera
  • M. Lozano
  • J. L. Vives-Corrons
  • C. Rozman
Original Article


Eleven patients with early CLL (two in Rai's stage 0, seven in stage I, and two in stage II) received aIFN (3 MU subcutaneously three times a week for a median of 8 months; range, 4–12) after their tumor mass had been reduced with intermittent chlorambucil. Following chlorambucil/aIFN administration, a significant reduction in blood lymphocyte counts (from 25.1±12.0×109/1 to 6.3±5.32×109/1;p<0.001) and in CD 19-positive cells (from 21.0±12.0×109/1 to 3.8±2.3×109/1;p< 0.001) was observed. Three of seven patients with stage-I and one of two with stage-II disease moved to stage 0, and a complete response (CR) was observed in two patients with stage-I at diagnosis. Overall, there were eight patients who, after treatment, had either a CR (2 cases) or stage-0 disease (6 cases), which compares favorably with two patients with stage-0 disease before entering the study (p=0.015). In five patients (including the two who achieved a CR) aIFN further improved the disease status achieved with chlorambucil.

Key words

Chlorambucil Alpha-2b interferon Chronic lymphocytic leukemia Treatment 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Balkwill FR (1987) Antitumor effects of interferons in animals. In: Finter NB, Oldham RD (eds) Interferon, vol 4. Elsevier, Amsterdam, p 225Google Scholar
  2. 2.
    Bloom ET, Korn EL (1983) Quantification of natural cytotoxicity by human lymphocyte subpopulations isolated by density: heterogeneity of the effector cells. J Immunol Methods 58: 323–335Google Scholar
  3. 3.
    Boussiotis VA, Pangalis GA (1988) Randomized clinical trial with alpha-2b interferon in 26 stage-A untreated B-chronic lymphocytic leukemia patients. Nouv Rev Fr Hematol 30: 471–473Google Scholar
  4. 4.
    Bunn PA, Foon KA, Ihde DC, Longo DL, Eddy J, Winkler CF, Veach SR, Zeffren J, Sherwin SA, Oldham R (1984) Recombinant leukocyte A interferon: an active agent in advanced cutaneous T-cell lymphomas. Ann Intern Med 101: 484–487Google Scholar
  5. 5.
    Cooper MR, Fefer A, Thompson J, Case DC jr, Kmepf R, Sacher R, Neefe J, Bickers J, Scarffe JH, Spiegel R, Bonnern E (1986) Alpha-2 interferon/melphalan/prednisone in previously untreated patients with multiple myeloma: a phase I-II trial. Cancer Treat Rep 70: 473–476Google Scholar
  6. 6.
    Einhorn S, Blomgren H, Jarstrand C, Stander H, Wasserman J (1983) Influence of interferon-alpha therapy on functions of the human immune system. In: De Maeyer E, Schellekens H (eds) The biology of the interferon system. Elsevier, Amsterdam, p 347Google Scholar
  7. 7.
    Foon KA, Bottino C, Abrams PG, Fer MF, Longo DL, Schoenberger CS, Oldham RK (1985) Phase-II trial of recombinant leukocyte A interferon in patients with chronic lymphocytic leukemia. Am J Med 78: 216–220Google Scholar
  8. 8.
    French Cooperative Group on Chronic Lymphocytic Leukemia (1990) Effects of chlorambucil and therapeutic decision in initial forms of chronic lymphocytic leukemia (stage A): results of a randomized clinical trial on 612 patients. Blood 75: 1414–1421Google Scholar
  9. 9.
    Giles FJ, Singer CRJ, Gray AG (1988) Alpha-interferon therapy for essential thrombocythaemia. Lancet 2: 70–72Google Scholar
  10. 10.
    Gutterman JU, Blumenschein G, Alexanian R, Yap H-Y, Bazdar AU, Cabanillas F, Hortobagyi GN, Hersh EM, Rasmussen SL, Harmon M, Kramer M, Potska S (1980) Leukocyte interferon induced tumor regression in human metastasic breast cancer, multiple myeloma, and malignant lymphoma. Ann Intern Med 93: 399–406Google Scholar
  11. 11.
    Horning SJ, Merigan TC, Krown SE, Gutterman JU, Louie A, Gallagher J, McCravey J, Abramson J, Cabanillas F, Oettgen H, Rosenberg SA (1985) Human interferon in malignant lymphoma and Hodgkin's disease. Cancer 56: 1305–1310Google Scholar
  12. 12.
    International Workshop on CLL (1989) Chronic lymphocytic leukemia: recommendations for diagnosis, staging, and response evaluation. Ann Intern Med 110: 236–238Google Scholar
  13. 13.
    Janssen JThP, De Pauer BE, Holdrinet RSG (1984) Treatment of hairy cell leukemia with recombinant alpha-2 interferon. Lancet 1: 1025Google Scholar
  14. 14.
    Lotzova E, Savary CA, Gutterman JU, Hersh EM (1982) Modulation of natural killer cell-mediated cytotoxicity by partially purified and cloned interferon alpha. Cancer Res 42: 2480–2485Google Scholar
  15. 15.
    McLaughlin P, Cabanillas F, Hagemeister F, Swan F, Romaguera J, Taylor S, Rodriguez A, Velasquez W, Redman J, Gutterman J (1990) Alpha-interferon prolongs remission in stageIV low-grade lymphoma. Proc Am Soc Clin Oncol 9: 267 (abstract)Google Scholar
  16. 16.
    Mandelli F, Avvisati G, Amadori S, Boccadoro M, Gernone A, Lauta V, Marmont F, Petrucci MT, Tribalto M, Vegna ML, Dammacco F, Pileri A (1990) Maintenance treatment with recombinant interferon alpha 2b in patients with multiple myeloma responding to conventional induction chemotherapy. N Engl J Med 322: 1430–1434Google Scholar
  17. 17.
    Minato N, Reid L, Cantor H, Lengyel P, Bloom BR (1980) Mode of regulation of NK activity by interferon. J Exp Med 152: 124–129Google Scholar
  18. 18.
    Molica S, Alberti A (1990) Recombinant alpha-2a interferon in treatment of chronic lymphocytic leukemia: a preliminary report with emphasis on previously untreated patients in early stage of disease. Haematologica (Pavia) 75: 75–78Google Scholar
  19. 19.
    O'Connell MJ, Colgan JP, Oken MM, Ritts RE, Kay NE, Itr LM (1986) Clinical trial of recombinant leukocyte A interferon as initial therapy for favorable histology non-Hodgkin's lymphomas and chronic lymphocytic leukemia: an Eastern Cooperative Oncology Group pilot study. J Clin Oncol 4: 128–136Google Scholar
  20. 20.
    Östlund L, Einhorn S, Robèrt K-H, Juliusson G, Biberfeld P (1986) Chronic B-lymphocytic leukemia cells proliferate and differentiate following exposure to interferon in vitro. Blood 67: 152–159Google Scholar
  21. 21.
    Panayiotidis PG, Boussiotis VA, Pangalis GA (1990) Immunologic findings in B-chronic lymphocytic leukemia patients treated with α2b-interferon. Leuk Lymph 1: 235–240Google Scholar
  22. 22.
    Paucker G, Cantell K, Henle W (1962) Quantitative studies on viral interference in suspended L cells. III. Effect of interfering viruses and interferon on the growth rate of cells. Virology 17: 324–328Google Scholar
  23. 23.
    Quesada JR, Reuben J, Manning JT, Hersh EM, Gutterman JU (1984) Alpha interferon for induction of remission of hairycell leukemia. N Engl J Med 310: 15–18Google Scholar
  24. 24.
    Quesada JR, Alexanian R, Hawkins M, Barlogie B, Borden E, Itri L, Gutterman JU (1986) Treatment of multiple myeloma with recombinant a interferon. Blood 67: 275–278Google Scholar
  25. 25.
    Rai KR, Sawitsky A, Cronkite EP, Chanana AD, Levy RN, Pasternack BS (1975) Clinical staging of chronic lymphocytic leukemia. Blood 46: 219–234Google Scholar
  26. 26.
    Rozman C, Montserrat E, Viñolas N, Urbano-Ispizua A, Ribera JM, Gallart T, Compernolle C (1988) Recombinant alpha-2 interferon in the treatment of B chronic lymphocytic leukemia in early stages. Blood 71: 1295–1298Google Scholar
  27. 27.
    Rozman C, Montserrat E (1990) Chronic lymphocytic leukemia: when and how to treat. Blut 59: 467–472Google Scholar
  28. 28.
    Schulof RS, Lloyd MJ, Stallings JJ, Mai D, Phillips TM, Jones GJ, Schechter GP (1985) Recombinant leukocyte A interferon in B-chronic lymphocytic leukemia: in vivo effects on autologous tumor activity. J Biol Response Mod 4: 310–323Google Scholar
  29. 29.
    Shustik C, Mick R, Silver R, Sawitsky A, Rai K, Shapiro L (1988) Treatment of early chronic lymphocytic leukemia: intermittent chlorambucil versus observation. Hematol Oncol 6: 7–12Google Scholar
  30. 30.
    Stiehm ER, Kronenberg LH, Rosenblatt HM, Bryson Y, Merigan TC (1982) Interferon: immunobiology and clinical significance. Ann Intern Med 96: 80–85Google Scholar
  31. 31.
    Talpaz M, Kantarjian HM, McCredie K, Trujillo JM, Keating MJ, Gutterman JU (1986) Hematologic remission and cytogenetic improvement induced by recombinant human interferon alpha A in chronic myelogenous leukemia. N Engl J Med 314: 1065–1069Google Scholar
  32. 32.
    Talpaz M, Rosenblum M, Kurzrock R, Reuben J, Kantarjian H, Gutterman J (1987) Clinical and laboratory changes induced by alpha interferon in chronic lymphocytic leukemia —a pilot study. Am J Hematol 23: 341–350Google Scholar
  33. 33.
    Urba WJ, Longo DL (1986) Alpha-interferon in the treatment of nodular lymphomas. Semin Oncol 13 [Suppl 5]: 40–45Google Scholar
  34. 34.
    Woorman CP, Catovsky D, Bevan PC, Camba L, Joyner M, Green PJ, Williams HJH, Bottomley JM, Gordon-Smith EC, Cawley JC (1985) Interferon is effective in hairy-cell leukaemia. Br J Haematol 60: 759–763Google Scholar
  35. 35.
    Ziegler-Heitbrock HWL, Schlag R, Flieger D, Thiel E (1989) Favorable response of early stage-B CLL patients to treatment with IFN-alpha2. Blood 73: 1426–1430Google Scholar

Copyright information

© Springer-Verlag 1991

Authors and Affiliations

  • E. Montserrat
    • 1
  • N. Villamor
    • 1
  • A. Urbano-Ispizua
    • 1
  • J. M. Ribera
    • 1
  • M. Lozano
    • 1
  • J. L. Vives-Corrons
    • 1
  • C. Rozman
    • 1
  1. 1.Postgraduate School of Hematology“Farreras Valentí”, Hospital Clinic, University of BarcelonaBarcelonaSpain

Personalised recommendations